Rosetta Genomics Ltd.
ROSGQ
Other OTC0.00
USD
- -
- -
Rosetta Genomics Ltd.
ROSGQ
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rosetta Genomics Ltd. is an Israel-based molecular diagnostics company specializing in the development and commercialization of microRNA-based diagnostic tests aimed at differentiating various cancer types. Its core product portfolio includes microRNA molecular diagnostic assays such as the miRview® mets2 test, which identifies the primary origin of metastatic tumors for cancers of unknown or uncertain primary (CUP), and miRview squamous, a test distinguishing squamous and non-squamous non-small cell lung cancer (NSCLC). The company’s tests measure the expression levels of specific microRNA biomarkers to provide precise cancer typing, thereby supporting oncology treatment decisions. Rosetta Genomics also provides pharmacogenomics testing under the PGxOne™ brand, predicting patient responses to chemotherapy based on genetic makeup. The company operates primarily through its CLIA-certified laboratories in the United States and Israel, focusing on oncologists, pathologists, and medical institutions worldwide. Founded in 2000 and headquartered in Israel, Rosetta Genomics leverages proprietary bioinformatics and microRNA research to develop its diagnostics platform. Recent significant developments include a co-marketing agreement with Precision Therapeutics, which amplifies commercial reach for the miRview® mets2 assay, bolstered by Medicare reimbursement decisions improving market access in the United States. The company has expanded its commercial and laboratory capacities to meet expected growth in demand for its oncology diagnostic tests. Rosetta also integrates a key strategic acquisition of Parkway Clinical Laboratories, a U.S.-based CLIA-certified lab, facilitating streamlined development, regulatory compliance, and commercialization of its microRNA-based tests. This acquisition supports operational control over diagnostics marketing, sales, and reimbursement strategies. Rosetta Genomics maintains strategic partnerships and collaborations with genomics service providers such as Admera Health, enhancing its sequencing-based oncology test offerings and enabling comprehensive genomic profiling for individualized cancer treatment. The company continues to invest in expanding test menus and advancing its diagnostic pipeline in molecular oncology diagnostic and therapeutic segments. Its technological foundation supports global commercialization efforts across North America, Europe, and Israel, serving a broad spectrum of cancer diagnostics and personalized medicine applications. Rosetta Genomics remains a key player in the emerging microRNA diagnostics market, focused on innovative products that address major unmet needs in cancer diagnosis and treatment monitoring.